Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines for conformational disorders.

Marcin Sadowski1, Thomas Wisniewski

  • 1Department of Neurology, New York University School of Medicine, 550 First Avenue, MHL Rm. HN 419, New York, NY 10016, USA. Thomas.Wisniewski@med.nyu.edu

Expert Review of Vaccines
|June 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same author

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same author

Interconnected influences of diet, gut microbiome, and metabolome on cognition across three metabolomics platforms.

Research square·2026
Same author

Short T1 Fraction as a Marker of Myelin Content: Evidence from Postmortem MRI and Histology.

bioRxiv : the preprint server for biology·2026
Same author

Amygdala microstructural changes in subjective cognitive decline: A diffusion kurtosis and neurite orientation dispersion and density imaging study.

Journal of Alzheimer's disease : JAD·2026
Same author

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.

Acta neuropathologica·2026
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Neurodegenerative disorders like Alzheimer's and prion diseases involve toxic protein misfolding. Promising new vaccines targeting these conformational changes show potential for improved treatment with fewer side effects.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Neurodegenerative disorders, particularly Alzheimer's disease and prion diseases, are increasing due to aging populations.
  • These are conformational disorders characterized by toxic protein misfolding and aggregation.
  • Prion diseases are fatal with no current treatment, and new variant Creutzfeldt-Jakob disease poses public health concerns.

Purpose of the Study:

  • To explore immune modulation as a therapeutic strategy for Alzheimer's disease and prion diseases.
  • To review the potential of vaccination in treating these neurodegenerative conditions.
  • To discuss novel vaccine strategies aimed at improving efficacy and reducing toxicity.

Main Methods:

  • Review of animal models for Alzheimer's disease and prion diseases demonstrating vaccine efficacy.

Related Experiment Videos

  • Analysis of a human Alzheimer's disease vaccine trial (A beta1-42) and its toxicity and benefit profiles.
  • Examination of the role of cell-mediated immunity in vaccine-induced toxicity.

    • Main Results:

    • Vaccination dramatically improved disease course in animal models of Alzheimer's and prion diseases.
    • A human Alzheimer's vaccine trial was halted due to toxicity, but cognitive benefits were observed in patients with a humoral response.
    • Excessive cell-mediated immunity was linked to toxicity in the human trial.

    Conclusions:

    • Immune modulation, particularly vaccination, is a promising therapeutic avenue for Alzheimer's disease and prion diseases.
    • Novel vaccine strategies are being developed to enhance efficacy while minimizing side effects.
    • Further research is needed to optimize vaccine design for safe and effective treatment of neurodegenerative conformational disorders.